$NKTR News

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nektar Therapeutics (NKTR) Could Be 71% Undervalued As Rezpegaldesleukin Data Extend Its Case

UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53

Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130

BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating

Nektar Therapeutics (NKTR) Shareholder/Analyst Call - Slideshow

Nektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And More

HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $185 Price Target

Nektar Posted Promising Alopecia Results. Here's Why It Took A 22% Beating.

NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge

Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial

/UPDATE -- Nektar Therapeutics/

Nektar Therapeutics (NKTR) Shareholder/Analyst Call Transcript

Nektar Therapeutics Presents Data On Rezpegaldesleukin From Its Phase 2b REZOLVE-A, Phase 2b REZOLVE-AD Trials At European Academy Of Dermatology And Venereology

New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis

How New Rezpegaldesleukin Durability and Mechanistic Data Could Impact Nektar Therapeutics (NKTR) Investors

What Could Nektar Therapeutics (NKTR) New Rezpegaldesleukin Data Mean For Its Case?

Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026

Nektar Therapeutics (NKTR) Dropped, So What Is Driving Attention Now?